Tower View Wealth Management LLC Buys 972 Shares of Danaher Corporation $DHR

Tower View Wealth Management LLC boosted its stake in shares of Danaher Corporation (NYSE:DHR) by 428.2% during the second quarter, Holdings Channel.com reports. The firm owned 1,199 shares of the conglomerate’s stock after purchasing an additional 972 shares during the quarter. Tower View Wealth Management LLC’s holdings in Danaher were worth $237,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in the stock. MGO One Seven LLC raised its stake in Danaher by 485.7% in the first quarter. MGO One Seven LLC now owns 25,098 shares of the conglomerate’s stock valued at $5,145,000 after buying an additional 20,813 shares during the last quarter. Chicago Capital LLC raised its stake in Danaher by 11.6% in the second quarter. Chicago Capital LLC now owns 13,332 shares of the conglomerate’s stock valued at $2,634,000 after buying an additional 1,391 shares during the last quarter. UniSuper Management Pty Ltd raised its stake in Danaher by 1.6% in the first quarter. UniSuper Management Pty Ltd now owns 170,505 shares of the conglomerate’s stock valued at $34,954,000 after buying an additional 2,667 shares during the last quarter. Asahi Life Asset Management CO. LTD. purchased a new stake in Danaher in the first quarter valued at about $539,000. Finally, Horizon Financial Services LLC raised its stake in Danaher by 20,400.0% in the first quarter. Horizon Financial Services LLC now owns 8,200 shares of the conglomerate’s stock valued at $1,681,000 after buying an additional 8,160 shares during the last quarter. Institutional investors own 79.05% of the company’s stock.

Danaher Stock Down 1.1%

Shares of DHR stock opened at $210.64 on Friday. The stock has a 50 day moving average of $200.00 and a 200 day moving average of $197.40. The company has a current ratio of 1.62, a quick ratio of 1.22 and a debt-to-equity ratio of 0.32. The stock has a market cap of $150.83 billion, a P/E ratio of 44.82, a P/E/G ratio of 3.03 and a beta of 0.77. Danaher Corporation has a twelve month low of $171.00 and a twelve month high of $279.41.

Danaher (NYSE:DHR) last announced its quarterly earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share for the quarter, beating the consensus estimate of $1.64 by $0.16. The company had revenue of $5.94 billion during the quarter, compared to analysts’ expectations of $5.83 billion. Danaher had a return on equity of 10.70% and a net margin of 14.21%.Danaher’s quarterly revenue was up 3.4% on a year-over-year basis. During the same period last year, the business earned $1.72 earnings per share. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. As a group, sell-side analysts expect that Danaher Corporation will post 7.63 EPS for the current year.

Danaher Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Friday, September 26th will be issued a $0.32 dividend. This represents a $1.28 annualized dividend and a yield of 0.6%. The ex-dividend date of this dividend is Friday, September 26th. Danaher’s dividend payout ratio (DPR) is presently 27.23%.

Insider Buying and Selling

In other Danaher news, Director Teri List sold 2,778 shares of the firm’s stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $211.06, for a total value of $586,324.68. Following the sale, the director directly owned 20,751 shares of the company’s stock, valued at approximately $4,379,706.06. This trade represents a 11.81% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 11.10% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on DHR shares. Robert W. Baird increased their price target on Danaher from $225.00 to $226.00 and gave the company an “outperform” rating in a research note on Friday, July 18th. Bank of America reduced their price objective on Danaher from $230.00 to $220.00 and set a “buy” rating for the company in a research note on Monday, September 22nd. Wells Fargo & Company reduced their price objective on Danaher from $210.00 to $205.00 and set an “equal weight” rating for the company in a research note on Wednesday, July 23rd. Wall Street Zen upgraded Danaher from a “hold” rating to a “buy” rating in a research note on Friday, June 27th. Finally, Evercore ISI reduced their price objective on Danaher from $230.00 to $226.00 and set an “outperform” rating for the company in a research note on Tuesday, July 8th. Seventeen equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $245.91.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.